Particle.news
Download on the App Store
9 ARTICLES
·
2w ago

Indivior to Abandon London Listing to Focus Solely on Nasdaq

Cutting the secondary London listing will reduce administrative costs by aligning share trading with where over 80% of its revenue is generated

Image
Image
The move represents another blow for the London market
Image

Overview

  • Indivior will cancel its secondary London listing on July 25, 2025, completing its shift to a single primary listing on Nasdaq.
  • More than 80% of Indivior’s net revenue comes from the US, led by Sublocade’s $756 million in sales last year.
  • Approximately 75% of share trades take place on Nasdaq and over 70% of investors are now US-based, the company says.
  • It faces multiple lawsuits over its opioid addiction treatments, including claims that Suboxone film was defectively designed and falsely marketed.
  • The move adds to a broader exodus in which 88 firms delisted or transferred primary listings from London last year, with only 18 new companies joining the market.